Table 1.
Patients’ characteristics, clinical manifestations and laboratory results in patients with Raynaud’s phenomenon
| Variables | Patients with Raynaud’s phenomenon (N = 64) |
|---|---|
| Characteristics | |
| Age (years old) | 50.9 ± 14.4 |
| Sex, female (N (%)) | 58 (90.6) |
| Raynaud’s phenomenon duration (years) | 5.3 ± 7.7 |
| Newly classified to systemic sclerosis by the 2013 ACR/EULAR classification criteria (N (%)) | 17 (26.5) |
| Autoimmune disease accompanied (N (%)) | 33 (51.6) |
| Sjögren syndrome | 15 (23.4) |
| Systemic lupus erythematosus | 8 (12.5) |
| Mixed connective tissue disease | 5 (7.8) |
| Rheumatoid arthritis | 3 (4.7) |
| Inflammatory myopathy | 2 (3.1) |
| Clinical manifestations (N (%)) | |
| Scleroderma (proximal) | 0 (0) |
| Puffy finger | 34 (53.1) |
| Sclerodactyly | 7 (10.9) |
| Digital tip ulcer | 2 (3.1) |
| Fingertip pitting scar | 0 (0) |
| Telangiectasia | 7 (10.9) |
| Abnormal nailfold capillaries | 46 (71.8) |
| Pulmonary arterial hypertension | 1 (1.6) |
| Interstitial lung disease | 5 (7.8) |
| Autoantibodies (N (%)) | |
| Antinuclear antibody (centromere) | 19 (29.7) |
| Anti-centromere antibody | 22 (34.4) |
| Anti-Scl-70 antibody | 2 (3.1) |
Values are expressed as N (%) or mean ± standard deviation. ACR, American College of Rheumatology; EULAR, The European League Against Rheumatism.